Pfizer's RSV Vaccine Approved Across EU—GSK Left Behind!

Pfizer just scored a major win in the vaccine race! 🧪💉
In this video, we break down the European Commission’s approval of Pfizer’s RSV vaccine, Abrysvo, for adults aged 18 to 59 at increased risk of RSV-related complications. This expanded approval now applies across all 27 EU countries, giving Pfizer a huge advantage over GSK, whose RSV vaccine is still awaiting approval for this group.

RSV (Respiratory Syncytial Virus) is a common but serious virus that poses significant risks to infants and older adults. Now, with the inclusion of younger high-risk adults, Pfizer's Abrysvo is positioned to make an even greater public health impact. 🏥✅

Plus, early real-world data from the UK shows a significant drop in hospitalizations among vaccinated older adults—suggesting strong vaccine effectiveness in real settings.

🔍 In this video, you'll learn:

What RSV is and why it's dangerous

Why Pfizer’s EU approval is a big deal

How this affects GSK and future vaccine rollouts

What this could mean for public health in Europe

👉 If you found this video helpful, don’t forget to like, comment, and subscribe to Pharma Tales for more updates on vaccines, public health breakthroughs, and the latest in pharmaceutical news.

#Pfizer #RSVVaccine #Abrysvo #GSK #EUVaccineApproval #PharmaNews #RSVExplained #HealthUpdate #Vaccines2025 #PublicHealth

Видео Pfizer's RSV Vaccine Approved Across EU—GSK Left Behind! канала PharmaTales